News Agency
Men's Weekly

TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

  • Written by PR Newswire
TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024
  • TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-life in a Phase 1 study than that of NovoSeven, a conventional hemophilia treatment for patients who develop inhibitors
  • TiumBio presented interim Phase 1a clinical data of TU7710 and discussed potential partnership at the ISTH 2024

SEONGNAM, South Korea, Jun...

Read more: TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710...

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion